# NK Cell Therapy for AML

> **NCT05256277** · PHASE1 · TERMINATED · sponsor: **Zhejiang University** · enrollment: 3 (actual)

## Conditions studied

- AML

## Interventions

- **DRUG:** CT101a

## Key facts

- **NCT ID:** NCT05256277
- **Lead sponsor:** Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-12-28
- **Primary completion:** 2022-08-28
- **Final completion:** 2023-04-03
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** A new study is planed to replace the current study due to IP upgrade
- **Last updated:** 2023-05-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05256277

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05256277, "NK Cell Therapy for AML". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05256277. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*